Skip to content
Search

Latest Stories

Leo Pharma appoints Leanne Walsh as General Manager and Vice President for UK and Ireland

Leo Pharma, one of the leaders in medical dermatology, has appointed Leanne Walsh as the new General Manager and Vice President for Leo Pharma United Kingdom and Ireland. 

Leanne joins from Aimmune Therapeutics where she was previously General Manager for Northern Europe.


She has over 20 years of experience in the pharmaceutical industry bringing innovation to patients at Global, European and affiliate level. She is passionate about patients, with expertise in building teams and access capabilities to drive successful commercialisation. She has a strong record of leading launches of life changing therapies in both competitive spaces and in complex, niche, specialist markets where she has demonstrated continued excellence to diagnose, improve and implement brand performance through marketing and selling excellence.

Discussing her appointment, Leanne commented,” I am excited to join the Leo Pharma UK and Ireland team. I firmly believe that Leo Pharma has the opportunity to be the preferred dermatology care partner and can exceed the expectations of both our partners and patients through transformation, dedication and a true partnership approach with all our stakeholders.

My key priorities in this role are to drive proactive innovation and nurture an inclusive work environment where all internal and external stakeholders are inspired to take action to improve the lives of those living with skin conditions. The medical dermatology industry is evolving rapidly, which presents real opportunities for Leo Pharma, and I look forward to the exciting journey ahead.” Leanne will start this role at Leo Pharma United Kingdom and Ireland on the 12th of June 2023.

More For You

RPS backs Pharmacist Support "Gift in Wills" initiative

The ‘Gift in Wills’ initiative is delivered in partnership with Bequeathed.

Photo credit: gettyimages

Leave a legacy: RPS partners with Pharmacist Support to promote ‘Gift in Wills’

The Royal Pharmaceutical Society (RPS) has announced its support for the ‘Gift in Wills’ initiative run by Pharmacist Support, coinciding with the charity’s birthday celebrations today (Tuesday 15 April).

This collaboration allows RPS members to create a free will while also helping to safeguard the future of vital support services for the pharmacy profession.

Keep ReadingShow less
Pharmacist Support calls for birthday donations to meet rising demand for mental health services

More and more pharmacy professionals are reaching out for help, said Danielle Hunt.

Pharmacist Support's birthday appeal: Donate to address growing mental health demand

Pharmacist Support – the independent charity dedicated to the pharmacy profession – is celebrating 184 years of service with the launch of a special birthday donations appeal.

On 15 April, the charity is urging individuals and organisations across the sector to support its campaign to raise vital funds to meet the increasing demand for its mental health and wellbeing services.

Keep ReadingShow less
Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less